Soligenix, Inc. (SNGX)
Market Cap | 14.46M |
Revenue (ttm) | n/a |
Net Income (ttm) | -10.36M |
Shares Out | 4.29M |
EPS (ttm) | -3.75 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 583,212 |
Open | 3.250 |
Previous Close | 3.360 |
Day's Range | 3.210 - 3.440 |
52-Week Range | 1.090 - 6.230 |
Beta | 1.96 |
Analysts | Strong Buy |
Price Target | 6.00 (+77.78%) |
Earnings Date | Aug 14, 2025 |
About SNGX
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflam... [Read more]
Financial Performance
In 2024, Soligenix's revenue was $119,371, a decrease of -85.78% compared to the previous year's $839,359. Losses were -$8.27 million, 34.6% more than in 2023.
Financial StatementsAnalyst Summary
According to one analyst, the rating for SNGX stock is "Strong Buy" and the 12-month stock price target is $6.0.
News

Why Is Soligenix Stock Soaring On Monday?
Soligenix, Inc. SNGX stock is higher on Monday after the U.S. Food and Drug Administration granted orphan drug designation to dusquetide, the active ingredient in SGX945, for Behçet's Disease.

FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results
Provides SGX945 Seven Years of U.S. Market Exclusivity Upon FDA Approval PRINCETON, N.J. , Aug. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopha...

Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results
PRINCETON, N.J. , Aug. 14, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer
AUSTIN, Texas, Aug. 08, 2025 (GLOBE NEWSWIRE) -- via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeuti...

Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease
Study results support advancing SGX945 in this difficult to treat orphan disease PRINCETON, N.J. , July 31, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage...

Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones
PRINCETON, N.J. , July 8, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to t...

Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions
Active Ingredient Manufacturing Transfer to the U.S. Complete PRINCETON, N.J. , July 1, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical ...

Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials
PRINCETON, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- via IBN – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing...

Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results
PRINCETON, N.J. , May 9, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to tr...

Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks
Interim Results from FDA-Funded Study Reinforces HyBryte's ™ Rapid Response and Strong Safety Profile PRINCETON, N.J. , April 14, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the ...

IBN Initiates Coverage of Soligenix Inc.
AUSTIN, Texas, March 25, 2025 (GLOBE NEWSWIRE) -- via IBN – Soligenix Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare disea...

Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants
Broader protection induced by combination of COVID adenovirus vaccine plus CiVax ™ compared to 2-shot mRNA vaccination series PRINCETON, N.J. , March 25, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq:...

Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results
PRINCETON, N.J. , March 21, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to...

HyBryte™ Treatment Studies Presented at Two Medical Conferences in March
Two Presentations Highlight Data Demonstrating Hypericin Photodynamic Therapy Potential with a Preliminary Comparison to Current Therapy PRINCETON, N.J. , March 6, 2025 /PRNewswire/ -- Soligenix, Inc....

Soligenix to Present at BIO CEO & Investor Conference
PRINCETON, N.J. , Feb. 4, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to t...

Soligenix to Present at Upcoming Investor Conferences
PRINCETON, N.J. , Jan. 16, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
Study Supported by $2.6 Million FDA Orphan Products Development Grant PRINCETON, N.J. , Jan. 14, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmac...

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
FLASH 2 Study opens patient enrollment PRINCETON, N.J. , Dec. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on dev...

HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment
Significant Efficacy against Plaque Lesions Also Demonstrated with HyBryte™ PRINCETON, N.J. , Dec. 2, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage bioph...

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma
Phase 3 clinical study of HyBryte ™ in CTCL initiating in 2024 PRINCETON, N.J. , Nov. 19, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical...

Soligenix to Present at November 21st Virtual Investor Summit Microcap Event
PRINCETON, NJ / ACCESSWIRE / November 15, 2024 / Soligenix, Inc. (Nasdaq:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease
Study DUS-AUBD-01 opens patient enrollment PRINCETON, N.J. , Nov. 14, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on ...

Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results
PRINCETON, N.J. , Nov. 8, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to t...

Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin
Active Ingredient in HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma and SGX302 for the Treatment of Psoriasis PRINCETON, N.J. , Oct. 22, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (S...

Soligenix Invited to Present at Upcoming Investor Conferences
PRINCETON, N.J. , Oct. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...